| Autor: |
Antonis Fanouriakis, Maria Tektonidou, George Bertsias, Dimitrios Boumpas, Petros Sfikakis, Prodromos Sidiropoulos, Dimitrios Vassilopoulos, Alexandros Garyfallos, Charalampos Papagoras, Pinelopi Konstantopoulou, Kyriaki Boki, Antonia Elezoglou, Maria Kosmetatou, Maria Pappa |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Mediterranean journal of rheumatology. 33(2) |
| ISSN: |
2529-198X |
| Popis: |
Lupus nephritis (LN) affects a significant proportion of patients with systemic lupus erythematosus (SLE) and is characterised by increased morbidity and mortality. The updated joint EULAR/European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) recommendations for the management of LN have set as target of therapy the optimisation (preservation or improvement) of kidney function, accompanied by a reduction in proteinuria of at least 25% by 3 months, 50% by 6 months, and below 500-700 mg/g by 12 months (complete clinical response). It is currently unknown what proportion of Greek patients with LN reach these proposed targets with the current available treatments. At the same time, recent successful phase 3 trials have led to the approval of both belimumab and voclosporin for the treatment of patients with LN and have steered discussions as to whether the "induction-maintenance" paradigm should be substituted by an early combination treatment for all patients. To inform future therapeutic decisions and facilitate the positioning of these new drugs in the therapeutic algorithm of LN, the current study protocol aims to map the unmet needs in the treatment of LN in Greece, by quantifying the proportion of patients who attain the recommended treatment targets in everyday clinical practice. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
